|
US2019388354A1
|
|
Improved compositions and methods for reducing overdose
|
|
CA2953225A1
|
|
Controlled extended release pregabalin
|
|
CA2910865A1
|
|
Compositions and methods for reducing overdose
|
|
CN105682649A
|
|
Compositions and methods for reducing overdose
|
|
CA2888278A1
|
|
Oral drug delivery formulations
|
|
EP2010162A1
|
|
Drug delivery composition
|
|
US2009220613A1
|
|
Controlled release delivery device comprising an organosol coat
|
|
WO2007112574A1
|
|
Extended release composition of venlafaxine
|
|
CA2579382A1
|
|
Controlled release delivery device
|
|
CA2576556A1
|
|
Drug delivery device
|
|
CA2571897A1
|
|
Controlled extended drug release technology
|
|
US2007065510A1
|
|
Novel controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
|
|
US2014010860A1
|
|
Abuse and alcohol resistant drug composition
|
|
US10064828B1
|
|
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
|
US2006039976A1
|
|
Controlled release composition using transition coating, and method of preparing same
|
|
US2006024361A1
|
|
Disintegrant assisted controlled release technology
|
|
US2006003007A1
|
|
Controlled extended drug release technology
|
|
US2007166370A1
|
|
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
|
CA2220038A1
|
|
Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances
|
|
CA2216215A1
|
|
Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
|
